At the WFH 2024 World Congress, the free paper sessions will feature authors presenting their abstracts as an oral presentation, followed by a Q&A period. The sessions will cover a wide range of topics, including the following:
- New products and novel therapies
- Women and girls’ health and research
- Quality of life and outcome research
- Von Willebrand disease (VWD)
- Gene therapy
- Clinical research and clinical trials
- Capacity building, advocacy and outreach models
- Orthopedic issues
- Physiotherapy and rehabilitation
- Nurse’s issues and care delivery
- Oral health
- Psychosocial issues
- And more!
To find out more about all the free paper sessions on offer at the WFH 2024 World Congress, click here.
Don’t miss the Christine Lee Young Researcher Award sessions
Established in 2012 by the WFH and Wiley, the Christine Lee Young Researcher Award is given in recognition to a top young researcher (graduate student or postdoctoral fellow) who is the primary author and presenter of a highly rated submitted abstract in any discipline involving hemophilia or other related bleeding disorders. A prize of $3,000 for the best free paper presentation and a prize of $1,000 for the best poster presentation, along with a three-year online personal subscription to Haemophilia, will be awarded to two deserving young researchers.
Authors will compete for the Christine Lee Award in the three sessions below.
The winners will be announced at the closing plenary on Wednesday, April 24, 2024 (16:30 to 17:00 CEST).
April 23, 2024, 11:30 to 12:30
- Fitusiran displays efficient pro-hemostatic activity in a mouse model of inducible factor X-deficiency, Geneviève McCluskey, France
- Evaluating the impact of the Self-BAT screening tool on referral outcomes. Results of the “Let’s Talk Period” project, Laura McDonald, Canada
- The lower double negative T cells proportion predicted the better high-titer inhibitors eradication outcomes of immune tolerance induction, Zhengping Li, China
- Bleeding profile and quality of life and women and girls with hemophilia, von Willebrand disease (VWD) and rare bleeding disorders, Nita Radhakrishnan, India
April 22, 10:45 to 11:30
- Better cost-effective outcome of intermediate-dose immune tolerance induction for severe hemophilia A children with high-titer inhibitors in developing countries: the interim report of a randomized multicenter clinical trial in China, Runhui Wu, China
- Towards tailoring the use of emicizumab for hemophilia A children in China: a retrospective clinical data from a comprehensive care center of China, Qianqian Mao, China
- Comparing desmopressin response classifications in 149 children with von Willebrand disease, Michael Shu, Canada
April 22, 15:15 to 16:00
- PRO management and collection outside clinical research: why is it so difficult?, Laura González-Rodríguez, Spain
- Effects of resistance training on muscle strength in adults with hemophilia: a systematic review and meta-analysis, Rodrigo Núñez-Cortés, Chile
- Final efficacy of adjunctive rituximab combined with low-dose immune tolerance induction in hemophilia A patients with inhibitor, Zekun Li, China
- Use of recombinant von Willebrand factor concentrate for peri-partum hemostatic management of women with type 2 VWD; a case series, Ozlem Turan, U.K.
Learn more about what the WFH 2024 World Congress has to offer by consulting the detailed program here. To find out more about Congress, please click here.